Q32 Bio Inc
$ 4.50
-1.75%
24 Feb - close price
- Market Cap 55,370,000 USD
- Current Price $ 4.50
- High / Low $ 4.69 / 4.41
- Stock P/E N/A
- Book Value -1.50
- EPS -3.40
- Next Earning Report 2026-03-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.34 %
- ROE -4.92 %
- 52 Week High 4.70
- 52 Week Low 1.34
About
Q32 Bio Inc. is an innovative biotechnology company dedicated to creating cutting-edge therapies for autoimmune diseases and improving immune responses. By leveraging its proprietary technology platform, Q32 Bio is advancing a pipeline of antibody-based therapeutics aimed at reestablishing immune system equilibrium. Supported by a seasoned management team and strategic partnerships, the company is strategically positioned to harness its scientific capabilities to meet critical unmet medical needs and enhance shareholder value, underscoring its commitment to research and development that aims to make a transformative impact in the healthcare sector.
Analyst Target Price
$15.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-06 | 2025-05-07 | 2025-03-11 | 2024-11-12 | 2024-08-08 | 2024-05-09 | 2024-03-13 | 2023-11-14 | 2023-08-14 | 2023-05-11 | 2023-03-09 |
| Reported EPS | -0.6 | -0.78 | -0.9 | -1.16 | -1.457 | -1.42 | -14.95 | -0.28 | -0.57 | -0.61 | -0.5 | -10.8 |
| Estimated EPS | -1.19 | -0.8 | -1.23 | -1.53 | -1.4 | -1.04 | -2.32 | -0.3 | -0.43 | -0.5 | -0.52 | -0.4922 |
| Surprise | 0.59 | 0.02 | 0.33 | 0.37 | -0.057 | -0.38 | -12.63 | 0.02 | -0.14 | -0.11 | 0.02 | -10.3078 |
| Surprise Percentage | 49.5798% | 2.5% | 26.8293% | 24.183% | -4.0714% | -36.5385% | -544.3966% | 6.6667% | -32.5581% | -22% | 3.8462% | -2094.23% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-10 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -1.06 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: QTTB
2026-02-21 12:40:14
Monaco Asset Management SAM significantly reduced its stake in Q32 Bio Inc. (NASDAQ:QTTB) by 47.4%, selling 280,800 shares. Despite this reduction, other institutional investors have recently acquired new positions, with Goldman Sachs Group Inc. notably increasing its stake. Insider transactions also show key executives, including the CEO and CFO, selling shares in December, though corporate insiders collectively still own a substantial portion of the stock.
2026-02-18 12:27:33
Q32 Bio (Nasdaq: QTTB) announced that its management will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, at 2:00 p.m. ET. A live webcast will be available, with an archived replay accessible for 90 days. The company's stock, QTTB, is trading above its 200-day moving average and the announcement follows recent strategic moves like asset monetization and previous conference participations that have positively impacted its stock price.
2026-02-18 00:27:53
Q32 Bio recently announced a registered direct offering of $10.5 million, involving common stock and pre-funded warrants, with proceeds aimed at funding working capital and advancing its alopecia areata trials. The offering, expected to close around February 18, 2026, includes participation from both new and existing institutional investors. Despite a "Neutral" rating from TipRanks' AI Analyst, Spark, due to weak financial performance, the company plans to use these funds to bolster its autoimmune pipeline.
2026-02-17 21:27:53
Q32 Bio Inc. has signed an agreement to issue and sell approximately 1.7 million shares of common stock at $3.90 per share, as disclosed by the SEC. This capital injection is intended to support the biotechnology company's research pipeline and operations.
2026-02-17 21:27:33
Q32 Bio has entered into an agreement for the issuance and sale of approximately 1.7 million shares. The shares will be sold at a price of $3.90 per share. This financial transaction was reported by Reuters via Refinitiv.
2026-02-17 18:58:50
Q32 Bio Inc has signed an agreement to issue and sell approximately 1.7 million shares of common stock at $3.90 per share, as disclosed by the SEC. This capital raise aims to inject new funds into the biotechnology company to support its research pipeline and operations.
